Objective: Cognitive outcomes in trials of postmenopausal hormone treatment have been inconsistent. Differing outcomes may be attributed to hormone formulation, treatment duration and timing, and differential cognitive domain effects. We previously demonstrated treatment benefits on visual cognitive function. In the present study, we describe the effects of hormone treatment on verbal outcomes in the same women, seeking to understand the effects of prior versus current hormone treatment on verbal function.
S
everal randomized controlled trials of hormone therapy have yielded results, indicating that there is little benefit of hormone use on postmenopausal cognition. There is still evidence that hormone treatment may, however, have positive effects on some cognitive domains under certain conditions defined by factors such as hormone formulation, dose, and treatment timing. [1] [2] [3] Results from animal studies provide compelling evidence of deleterious effects of estrogen depletion on the brain, and several observational studies have upheld the hypothesis that hormone treatment may positively impact cognitive functions after menopause. 2, [4] [5] [6] [7] [8] [9] [10] Similarly, early results from the new Early vs Late Intervention Trial with Estradiol (ELITE) study indicate that postmenopausal estradiol (E 2 ) treatment reduces negative effects of stress on working memory in a group of women with a mean age in their mid-60s. 11 Cognitive outcomes in randomized clinical trials, however, have not consistently benefited from treatment. Variability of cognitive outcomes between trials has been attributed to a number of factors, including hormone dose or formulation, treatment timing and duration, study participant age, and differences in study methodologies. Importantly, methods of cognitive assessment differ greatly across studies, and may not separately assess verbal, visual, and executive cognitive domains. It is therefore not clear whether hormone treatment uniformly affects cognitive function across domains, even in those studies demonstrating positive cognitive outcomes. We previously demonstrated a positive effect of at least 10 years of estrogen (ET) or estrogen þ progestin (EPT) treatment on visual cognitive function in women who began treatment soon after menopause. 12 In the present study, we describe the effects of hormone treatment (ET or EPT) on verbal cognitive outcomes in the same group of women.
Although many observational studies have suggested positive cognitive effects of postmenopausal hormone treatment, results from randomized trials have been variable and less encouraging. The Women's Health Initiative Memory Study (WHIMS) found that in women older than 65 years, the risk of dementia and cognitive decline was increased in those who were randomized to either estrogen alone or combined estrogen and progestin versus placebo [13] [14] [15] ; however, the results of the study are not necessarily generalizable to the younger perimenopausal population or to newly postmenopausal women. A follow-up analysis to the WHIMS study found no cognitive risk (or benefit) in women who had begun hormone treatment at age 50 to 54. 1 Cognitive function was assessed in the WHIMS study using the Modified MiniMental State Examination (3MSE) of global cognitive function, and did not allow for comparison of hormone effects on distinct cognitive domains. A later cognition-specific addition to this study, the Women's Health Initiative Study of Cognitive Aging (WHISCA) did not find benefits to visual or verbal cognitive function from treatment with estrogen or combined hormone treatment in the same group of women, and saw modest decreases in some tests of verbal ability after 3 years of treatment. 16 Many studies measuring effects of hormone treatment on cognitive outcomes use a global measure of executive function or risk of dementia as a cognitive endpoint, although a subset of studies separately assessed distinct cognitive domains. One study of 68 women found that women treated with 17b-E 2 had better verbal memory performance than women treated with conjugated equine estrogens (CEE). The Kronos Early Estrogen Prevention Study (KEEPS) recently, however, reported results from their ancillary cognition study, and found that compared with placebo, neither CEE nor E 2 with micronized progesterone had a positive or negative effect on verbal or visual cognitive function in women beginning treatment within a few years of the menopausal transition and after 4 years of treatment. 17, 18 Across cognitive domains, verbally based functions have been shown to be impacted by hormonal fluctuations associated with menopause. 19, 20 We previously demonstrated that verbal function is more influenced by women's menopause status than by age. 21 Specifically, in a cross-sectional sample of untreated pre-, peri-, and postmenopausal women, reduced verbal fluency was noted with advancing menopause status and was correlated with FSH levels and regional brain activation patterns, but was not associated with age. 21 Despite the evidence that verbal function is impacted by circulating hormone levels, trials of hormone treatment, even when limited to women in early menopausal years, show inconsistent verbal outcomes. A prospective observational study of perimenopausal women found that early, continuous hormone users had enhanced verbal memory performance compared with never-users, as measured with hippocampal activation on functional magnetic resonance imaging (fMRI) during a verbal memory test. 22 A randomized trial of hysterectomized, middle-aged, postmenopausal women, however, found no immediate verbal cognitive benefit after 6 months of ET. 23 Similarly, in a trial of older postmenopausal women (ages 61-87 y), combined estrogen and progesterone treatment did not improve verbal recall after 2 years of treatment, although continued hormone treatment did seem to slow declines in verbal ability in subsequent years, only in women who scored above average in initial baseline assessments. 24 Although these findings are not consistent with the critical window hypothesis, they suggest that exposure to hormone therapy even when continued long after menopause may benefit women with normal verbal cognitive function.
The present study is a cross-sectional evaluation of verbal memory, using neuropsychological testing and fMRI of a verbal discrimination task, in early-initiated, long-term, current, and past hormone users, compared with never-users. We sought to assess verbal cognitive function in postmenopausal women with prior versus current hormone use, and hypothesized that both current and prior hormone treatment would be associated with higher verbal cognition.
METHODS
This was a cross-sectional study of postmenopausal earlyinitiated long-term hormone users, both past and current, compared with never-users. The University of Michigan Institutional Review Board approved all procedures, and written informed consent was obtained from all participants.
Participants
Healthy, right-handed postmenopausal women over the age of 60 years were recruited by advertisement or through the University of Michigan Women's Health Registry. 25, 26 Participants underwent medical, psychiatric, and physiological screening before study participation. Screening laboratory tests included electrolytes, glucose, complete blood count, TSH, and E 2 , and a neuropsychological battery of tests was given to exclude the presence of dementia, including the Mini-Mental State Examination, 27 a brief screening measure of dementia, the Shipley Institute of Living Scale, 28 a short estimate of intellectual power, and the Geriatric Depression Rating Scale, 29 to exclude the presence of depression. Women were excluded for acute illness, diabetes, heart disease, cancer, or stroke, neurologic, psychiatric, or acute medical illness, centrally acting medications, intermittent estrogen or phytoestrogen supplements, tobacco use within 5 years, and contraindications to MRI (claustrophobia, pacemakers, or metallic implants or devices); however, women with hypertension or hypercholesterolemia were included. Women had HORMONE USE DOES NOT IMPROVE VERBAL FUNCTION either taken hormones continuously for a minimum of 10 years or had never received hormone therapy. All hormone users had begun therapy within 2 years of menopause, which was defined as the absence of menses for 1 year, the onset of severe menopausal symptoms after hysterectomy, or the surgical removal of ovaries at the time of hysterectomy. All hormone users received 0.625 mg/d CEE (Premarin, Wyeth Pharmaceuticals, Philadelphia, PA) with (EPT users) or without (ET users) cyclic or continuous medroxyprogesterone acetate (Provera, Pfizer, New York, NY, or Prempro, Wyeth Pharmaceuticals). Fifty-seven women were included in the study: 17 ET users, 21 EPT users, and 19 never-users. Women in the hormone therapy group (n ¼ 38) included current (13) and prior (25) long-term users. For women no longer taking hormones, the mean time since treatment ended was 1.88 AE 1.67 years. E 2 concentrations were measured with a modified off-line ACS:180 E 2 -6 immunoassay (Bayer Diagnostics Corp., Northwood, MA).
fMRI verbal discrimination and recall task
Episodic verbal discrimination processes were assessed during the fMRI scanning session using the levels of processing verbal discrimination paradigm, in which the women were asked to judge words based on physical characteristics (shallow processing) or on word meanings (deep processing). 30 Sixteen lists of 12 words each were equated for letter length and frequency, with 4 counterbalanced lists presented in each of 4 scanning runs. Each list was preceded by 8 seconds of instructions, and each word was presented for 1.5 seconds with a 1.5-second interstimulus interval. In the phonemic condition, participants decided whether each word was presented in uppercase or lowercase letters (shallow processing). In the semantic condition, participants decided whether each word represented an abstract or concrete concept (deep processing). Each list contained equal numbers of uppercase, lowercase, abstract, and concrete words. Responses were made by buttonpress with the right hand. Verbal tasks were presented on a computer monitor through radio frequency-shielded goggles mounted to a head coil (Resonance Technology Inc., Northridge, CA). To minimize performance differences, participants practiced tasks before the scanning session until they achieved at least 70% accuracy. After the scanning session participants performed a verbal recall task, in which they were presented with a series of words, half of which had been previously presented during the verbal discrimination task, and asked to indicate if they recalled seeing each word during the verbal discrimination task.
Neuropsychological assessment of verbal cognitive function
Verbal cognitive function was assessed using the Hopkins Verbal Learning Test (HVLT-R), 31 administered by a trained psychometrician, which assess verbal list learning, recall, and recognition. In this task, a list of 12 words is presented 3 times with participants asked to recall the words after each presentation, with the total number of words recalled across all three trials recorded. Participants are asked to recall the words again after 20 minutes, and asked to indicate recognized words from a list consisting of presented and unpresented words.
fMRI acquisition and processing
Scans were acquired using a 3-T whole-body MRI scanner (General Electric, Milwaukee, WI) equipped with a standard head coil. Anatomical MRI scans were acquired axially with a spoiled gradient recalled three-dimensional volumetric acquisition (repetition time, 9.6 ms; echo time, 3.3 ms; inversion recovery preparation, 200 ms; flip angle, 178; bandwidth, 15.63 Hz; 24-cm field of view; 1.5-mm slice thickness; 106-110 slices; 256 Â 256 matrix; two excitations). fMRI acquisition was sensitized for the blood oxygen level-dependent (BOLD) effect using a T2Ã-weighted single-shot spiral pulse sequence with 32 oblique-axial slices prescribed to be approximately parallel to the anterior commissure-posterior commissure line (spiral gradient echo: echo time, 25 ms; repetition time, 2,000 ms; flip angle, 608; 4-mm-thick contiguous slices; 24-cm field of view; 64 Â 64 image matrix). Image reconstruction included processing steps to remove distortions caused by magnetic field inhomogeneity and other sources of misalignment to the structural data. 32 Data were syncinterpolated in time, slice by slice, to correct for the staggered sequence of slice acquisition. 33 The first four functional volumes of each run were discarded to remove magnetic saturation effects, and the remaining images were realigned to the fifth volume to eliminate movement artifacts using SPM2-based algorithms. 34 Realignment parameters for each participant were examined to ensure that head movement did not exceed 2 mm. Anatomical and functional images were coregistered to each other through rigid body affine transformation using a mutual information algorithm, as previously described. 35 The participant's MRI was spatially normalized into standard stereotactic space via linear and nonlinear warping, to a minimal deformation template derived from T1-weighted magnetic resonance images from 25 normal older women, created by the Imaging of Dementia and Aging Laboratory at the University of California, Davis. 36 The transformation matrix was applied to all functional images, and a three-dimensional Gaussian smoothing kernel set at 8 mm full-width at half-maximum was applied to accommodate for residual anatomical variability and improve signal-tonoise ratios.
Data analysis
fMRI data analyses were conducted using the general linear model (GLM) in statistical parametric mapping imaging software (SPM, Department of Cognitive Neurology, Wellcome, London, UK). For the first-level analysis, contrast images were generated for each participant to assess activation differences between task conditions. For verbal processing task image analysis, initial contrast images (deep encoding-shallow encoding) were subtracted to isolate the deep encoding component, which was then used to assess effects of hormone treatment on deep verbal discrimination BERENT-SPILLSON ET AL and encoding. We performed initial one-sample t tests to evaluate effects of hormone treatment status in our study sample, including regions as significant with a false discovery rate (FDR)-corrected P < 0.001, using cluster-level threshold of P ¼ 0.001. Two-sample t tests were then performed to compare activation patterns between hormone ever-users and never-users, and between past and current hormone users, including regions as significant if they were present in the initial one-sample t-test analysis and P < 0.001 before correction for multiple comparisons. We only examined regions significantly different at the voxel level to reduce concerns of false positives associated with cluster-level comparisons. 37 Beta values were extracted from regions meeting these criteria for significant activation for use in secondary analyses. Clinical, demographic, and behavioral variables were compared between hormone treatment groups using two-sample ttest analyses. Associations between clinical, behavioral, and regional activation were determined using Pearson's correlational analyses. Because mean age was nearly identical across all groups, and women who were ever or never treated with hormones had similar levels of education, we did not include these variables as covariates in analyses.
RESULTS

Demographic and clinical characteristics
Demographic and clinical characteristics are provided in Table 1 
Neural activation during verbal discrimination task
Across the entire group, semantic discrimination during the fMRI verbal processing task elicited neural activation in cognitive processing regions of the brain (Table 2A) . These regions included the left inferior frontal cortex (Montreal Neurological Institute [MNI] coordinates À44, 22, À4, T ¼ 7.31, FDR-corrected P < 0.001), bilateral prefrontal cortex (50, 28, 20, T ¼ 6.32, P < 0.001 right; À40, 20, 20, T ¼ 8.14, P < 0.001 left), superior frontal cortex (À2, 30, 50, T ¼ 6.92, P < 0.001), thalamus (À12, À6, 16, T ¼ 5.15, P < 0.001), and the left occipital/parietal junction (À26, À62, 32, T ¼ 5.12, P < 0.001). When compared with never-treated women, women ever treated with hormones had more activation during the task in the left inferior frontal cortex (À54, 14, À6, T ¼ 3.72, uncorrected P < 0.001), and right prefrontal cortex (6, 54, À2, T ¼ 3.53, uncorrected P < 0.001), whereas never-treated women had no regions with significantly more activation during the task than ever-treated women (Table 2B ). Past and current hormone users did not have significant differences in activation patterns (Table 2C ).
Verbal cognitive function and behavioral correlates
All groups had similar accuracy on the fMRI deep verbal discrimination and verbal recall tasks (verbal discrimination: 85.30 AE 5.87% correct never-treated, 81.72 AE 11.57% evertreated, P ¼ 0.137; 83.82 AE 10.05% currently treated, 80.79 AE 12.25% past treated, P ¼ 0.478; verbal recall: 65.45 AE 7.49% never-treated, 62.21 AE 8.73% ever-treated, P ¼ 0.181; 61.56 AE 10.25% current treatment, 62.55 AE 8.05% past treatment, P ¼ 0.746). Ever-treated women took longer than never-treated women to form responses to both the verbal discrimination and verbal recall tasks (verbal discrimination reaction time: 1.02 AE 0.11 s never-treated, 1.10 AE 0.17 s ever-treated, P ¼ 0.035; verbal recall reaction time: 1.03 AE 0.13 s never-treated, 1.16 AE 0.16 s ever-treated, P ¼ 0.007), whereas current and past treated women had similar reaction times for both tasks (verbal discrimination reaction time: 1.03 AE 0.16 s current treatment, 1.14 AE 0.16 past treatment, P ¼ 0.68; verbal memory reaction time: 1.17 AE 0.15 s current treatment, 1.15 AE 0.17 s past treatment, P ¼ 0.724) ( Table 3) . Although there were no differences between groups on the neuropsychological measures of cognitive function (Table 3) , HVLT-delayed verbal memory scores were negatively correlated with activation during the verbal discrimination task in the posterior cingulate (R ¼ À0.328, P ¼ 0.048). Posterior cingulate activation during the task was also correlated with reaction times on the verbal discrimination task (R ¼ 0.323, P ¼ 0.015) and verbal memory task (R ¼ 0.272, P ¼ 0.043). E 2 levels were negatively correlated with the HVLT verbal learning test (R ¼ À0.270, P ¼ 0.044) (Fig. 1) .
DISCUSSION
Deficiencies in cognitive functioning experienced during and after menopause are associated with changes in the hormone environment and reduced circulating estrogen levels, independent of age. 21 Trials of menopausal hormone treatment, however, have not consistently demonstrated a positive impact on cognitive performance. Timing of treatment onset, treatment duration, and hormone formulation have been implicated in differences in cognitive outcomes between studies. In the present study, we addressed verbal cognitive function in women who had previous or current use of hormone treatment for at least 10 years, and beginning within 2 years of menopause, compared with women who had never experienced postmenopausal hormone treatment. We used a combination of neuropsychological assessments of verbal function and regional synaptic activity during a test of verbal discrimination as indirectly assessed with functional MR BOLD imaging. Women in the study performed similarly in neuropsychological assessments of verbal function; however, women currently or previously treated with hormones (E only or 
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EþP) had more regional brain activity during the verbal discrimination task than women never treated with hormones. Increased regional activity was localized to the left inferior frontal cortex and right prefrontal cortex, which are areas associated with verbal cognitive processing and executive control of cognitive function. Functionally, women ever treated with hormones performed slightly worse on the deep verbal processing task, took longer to formulate responses, and were less accurate at remembering previously viewed words than women never treated with hormones. In addition, increased regional brain activity in the posterior cingulate during the verbal processing task was positively correlated with longer response times, and was associated with worse delayed verbal recall task performance, suggesting that increased activation was associated with less efficient cognitive processing. This pattern is consistent with previous findings from our group that progression through the menopausal transition is associated with increased activation during the same verbal processing task and with worse performance on measures of verbal cognitive function, again consistent with less efficient neural processing. 21 Overall, current and past hormone users performed similarly on tests of verbal function and on the verbal discrimination task during the scanning session, and had similar activation patterns during the verbal discrimination task. The ''critical window hypothesis'' suggests that treatment with hormones near the time of menopause may have lasting cognitive benefits that persist beyond treatment discontinuation. 2, 38 This hypothesis is supported by an animal model, demonstrating that short-term exposure to E 2 in middle-aged rats improved memory up to 7 months after exposure, 39 and by a cross-sectional analysis of women aged 60 to 89 that found significantly better verbal memory in women with any history of prior hormone therapy. 40 Not all trials, however, have supported this hypothesis, for example, in a study of women with 7 years of early menopausal CEE with or without MPA treatment, there were no cognitive differences compared with placebo 7 years after ending treatment. 41 We did not find behavioral differences in verbal cognitive function between current and past hormone users in our study. Differences in regional activity in cognitive association networks (prefrontal, thalamic, and occipital areas) during the verbal discrimination task, however, suggest that there may be underlying neurobiological differences between current and past hormone user groups, albeit not linearly associated with neuropsychological measures of verbal function and with implications not clarified in the present study.
In our sample, hormone formulation may be a contributing factor to relatively worse performance in women ever treated compared with those never treated with hormones. A previous study comparing CEE to 17b-E 2 found more favorable effects of 17b-E 2 on verbal memory performance in women at risk 
FIG. 1.
In the entire group of women, regional brain activation during the deep encoding component of the verbal discrimination task (top images from left to right, left inferior frontal cortex, right prefrontal cortex, and posterior cingulate, with statistical intensities as represented by the T score color bar) was correlated with demographic, verbal discrimination task, and neuropsychological tests of verbal learning and memory. Bold numbers are statistically significant at P < 0.05 ( for AD, and conversely, a pattern of increased neural activation during a visual encoding task in both CEE and E 2 users compared with nonusers, interpreted as better neural function in the hormone-using groups. 17, 42, 43 This is consistent with animal studies that have demonstrated that E 2 improves memory by promoting synaptic density and increasing long-term potentiation in the hippocampus of ovariectomized rats. 44, 45 A related study in postmenopausal women has determined that depleting E 2 with an aromatase inhibitor decreased hippocampal activation during memory encoding and comparatively worse scores for verbal over visual recollection. 46 The recently released cognitive results from the Kronos Early Estrogen Prevention Study (KEEPS) found that neither CEE nor E 2 , along with progesterone improved verbal cognitive function compared with placebo, after 4 years of treatment initiated within 3 years of final menstrual period. 18 We previously found that ever-use of postmenopausal hormones was associated with increased regional brain activation during a visual memory task, and that regional activation was associated with better performance on the task, in the same group of women described in the present study.
12 Also in this same group of women, we found increased resting cholinergic activity in the hippocampus and the posterior cingulate in EþP-treated women, consistent with preservation of cholinergic activity and neuronal integrity in the EþP group. 47 Although the verbal discrimination task used in this study was also associated with greater regional activation in ever-treated women, behavioral data indicate that this increased activation was associated with worse performance on the verbal task. Ever-treated women also had longer response times than never-treated women, and the corresponding activity in the brain regions used for cognitive processing may indicate increased effort required to formulate responses to words presented during the task. Differential effects of hormone use across cognitive domains has been reported in other studies. A study of cognitive function in women who had experienced premature menopause found that hormone treatment at the time of menopause was associated with better visual cognitive function but worse verbal function after age 65. 48 A separate study of postmenopausal women with cognitive complaints found no effect of CEE with or without MPA treatment on visual function but modest negative effects on verbal cognition, compared with placebo. 49 Progestin may also have contributed to our findings of relatively worse verbal function in hormone ever-users. A study of cognitive function after 12 weeks of treatment with CEE plus MPA, micronized progesterone, or placebo found that women treated with CEE þ micronized progesterone outscored other treatment groups in tests of working memory, but demonstrated significantly decreased delayed verbal memory compared with pretreatment testing. 50 Strengths of this study include the comparison of consistent hormone users to never-users, with separate analyses of women with current or past hormone use. Our study included both ET (for women with hysterectomy) and EPT. All women were on identical hormone doses and formulations. This assessment of long-term use required a cross-sectional design because randomization to long-term hormone use was not feasible. Our study examined the effects of chronic, rather than acute, hormone use and thus allowed inclusion of both current and past hormone users; women falling into these groups were demographically similar. We did not include a comparison group of women who began hormone use well past menopause, but limiting our study to women who began hormone use early allowed us to include only women who used hormones long term. A limitation of this design is the inability to separate the effects of early initiation from those of long-term use of hormones. We also studied a relatively small sample, however sensitivity of fMRI imaging technologies allows detection of small differences in regional brain activation between groups. 51 Onset of menopause was selfdefined, although, whenever possible, we confirmed dates with healthcare records.
CONCLUSIONS
Our study results indicate that postmenopausal hormone use may not benefit verbal cognitive function, although current and past hormone use is associated with differences in neural pathways used while assessing verbal semantic distinctions. In the same group of women, we previously found evidence of improved visual cognitive function in both ET and EPT users, suggesting that the cognitive impacts of postmenopausal hormone use are domain specific.
